ERBB2 and gastric cancer: The preliminary study confirmed that Les-4367 showed the highest cytotoxic activity in gastric cancer cells; therefore, it was subjected to a broader analysis for its molecular mechanism of action in monotherapy and in combination with anti-HER2 antibodies (pertuzumab, trastuzumab).